Natural product-derived PD-1 pathway blockade for Human cancer therapy: Vitalboside A, isolated from Syzygium cumini, decreases the activity of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 12/April/2017, 8.09 am

Natural product-derived therapy for glucose homeostasis and TIIDM: Genistein, isolated from a variety of soy products, increases Barr2 expression, augments the functional activity of CAMKII, increases insulin secretion, promotes glucose homeostasis, prevents progression to TIIDM and ameliorates obesity-associated metabolic deficits via down regulation of its target gene, 12/April/2017, 12. 00 am
April 11, 2017
Natural product-derived therapy for glucose homeostasis and TIIDM: Paeoniflorin (PF), isolated from Paeonia Lactiflora, increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of their target gene, 12/April/2017, 8.43 am
April 12, 2017
Show all

Introduction:What they say

A recent study from Cell Signalling Section, Division of Immunology, Department of Pathology, Tennis Court Road, University of Cambridge, Cambridge CB2 1QP, UK shows that “Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8(+) Cytolytic T Cell Responses.” This study was published in the 16 February 2016 issue of Immunity (one of the best journals in Immunology with an impact factor of 20+) by Prof Rudd CE, Taylor A and others.


What we say

price-50[easy_payment currency=”USD”]

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived PD-1 pathway blockade for Human cancer therapy: Vitalboside A, isolated from Syzygium cumini, decreases the activity of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene


What is known?

It has recently been shown that blocking PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year.


Research Findings

This study suggests a natural product-derived therapy for human cancers. Vitalboside Aby inhibiting the activity of Glycogen synthase kinase 3-β (fig 1), it may: (a) increase transcription factor T-bet expression; (b) inhibit co-inhibitory receptor PD-1 expression;  (c) increase CD8(+) cytotoxic T lymphocyte function; (d) augment anti-tumor activity; & (e) inhibit metastatic cancer progression (figs. 1-3)

Image result for Vitalboside A

Fig 1 Vitalboside A serves as an anti-tumor immunity booster. Vitalboside A increases T-bet expression, inhibits PD-1 expression, and augments anti-tumor immunity

Image result for Syzygium cumini

Figure 2. Syzygium cumini

Image result for Syzygium cumini

Figure 3. Syzygium cumini. Vitalboside A, found in Syzygium cumini, augments anti-tumor immunity via down regulation of PD-1


Therapeutic opportunity

Thus, pharmacological formulations encompassing Vitalboside A  or its analogues either alone or in combination with other drugs may be used to inhibit the progression of tumors.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $50

Undisclosed mechanistic information: How does  Vitalboside A suppress the expression of PD-1 to promote anti-tumor immunity?

# Research cooperation

For purchase and payment information, you may reach us at admin@genomediscovery.org


References:

Citation: Boominathan, L., Natural product-derived PD-1 pathway blockade for Human cancer therapy: Vitalboside A, isolated from Syzygium cumini, decreases the activity of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target genee, 12/April/2017,  8.08 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.